GIMBHI’s daily mental health update — 10/16/26

🔄 Newport Healthcare brings back former CEO, lays off staff (Behavioral Health Business) — 10/16/26
TL;DR: Nashville-based Newport Healthcare is replacing CEO Brian Setzer with his predecessor, Joe Procopio. It’s also cutting 104 administrative staff and closing more locations as it shifts toward outpatient care.

🤝 Hungry for scale, wary of reimbursement: the behavioral health M&A dilemma (Behavioral Health Business) — 10/15/26
TL;DR: In a BHB survey, more than half of behavioral health providers said they are pursuing or open to acquisitions. Reimbursement uncertainty, including 2027 Medicaid cuts, remains the biggest factor holding deals back.

🍄 Can durable response to psilocybin reshape treatment-resistant depression care? (Psychiatric Times) — 10/16/26
TL;DR: London-based Compass Pathways shared 26-week phase 3 data showing its psilocybin therapy COMP360 delivered lasting symptom relief for some patients with treatment-resistant depression, with no new safety findings.

🧪 Podcast: Using antipsychotic plasma levels to guide schizophrenia treatment (Psychiatric Times) — 10/16/26
TL;DR: UC San Diego psychiatrist Jonathan Meyer says antipsychotic blood levels help spot nonadherence and guide dose increases, and that they tell clinicians more than pharmacogenetic testing.